UK may revise rules on "specials"
This article was originally published in Scrip
Executive Summary
The UK medicines regulator, the MHRA, wants to iron out the rules governing the manufacture and importation of unlicensed medicines. A recent consultation document outlines regulatory challenges at the fringes of the pharmaceutical market and possible shapes for new legislation in this area.